26 July 2018 
EMA/CHMP/518362/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Blincyto 
blinatumomab 
On 26 July 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Blincyto. 
The marketing authorisation holder for this medicinal product is Amgen Europe B.V. 
The CHMP adopted an extension of indication as follows: 
"Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older 
with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or 
in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic 
hematopoietic stem cell transplantation.” 
For information, the full indications for Blincyto will be as follows2: 
“Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome 
negative CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).  
Blincyto is indicated as monotherapy for the treatment of paediatric patients 
aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell 
precursor ALL which is refractory or in relapse after receiving at least two prior 
therapies or in relapse after receiving prior allogeneic hematopoietic stem cell 
transplantation.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
                                                
